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Abstract
Among gonococcal isolates examined at the Hawaii State Laboratory Division from 2003 to 2011, 
the prevalence of elevated cefixime minimum inhibitory concentrations (MICs; ≥0.064 μg/mL) 
and elevated cefpodoxime MICs (≥0.19 μg/mL) increased over time. In contrast, few isolates 
exhibited elevated ceftriaxone MICs (≥0.094 μg/mL), and the prevalence of elevated ceftriaxone 
MICs did not change.
Neisseria gonorrhoeae has progressively acquired resistance to many of the antimicrobial 
agents that were previously recommended for treatment, including sulfonamides, penicillin, 
tetracycline, and fluoroquinolones. Consequently, these antimicrobials are no longer 
recommended for treatment of gonorrhea in the United States.1,2 Since the emergence of 
fluoroquinolone resistance in the 2000s, third-generation cephalosporins have been the 
backbone of Centers for Disease Control and Prevention (CDC)–recommended gonorrhea 
treatment regimens. However, decreased gonococcal susceptibility to third-generation 
cephalosporins has been observed for more than 10 years in Asia3,4 and, more recently, in 
Europe and the United States.2,5 As of 2012, oral cephalosporins are no longer 
recommended as first-line treatment for gonorrhea in the United States; dual treatment with 
ceftriaxone and either azithromycin or doxycycline is the only CDC-recommended 
regimen.2 The emergence and spread of cephalosporin-resistant N. gonorrhoeae would 
further limit treatment options for gonorrhea and significantly impair infection control 
efforts.
Fluoroquinolone resistance in N. gonorrhoeae in the United States first emerged in Hawaii 
and then spread to the west coast and throughout the country.6 A similar trend was observed 
for the emergence of penicillinase-producing N. gonorrhoeae in the United States, with 
evidence of importation from Asia and most early cases detected in California and 
Hawaii.7,8 There is concern that this pattern will repeat with the emergence of cephalosporin 
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resistance. In 2001, Hawaii was the first state to report a cluster of multidrug-resistant N. 
gonorrhoeae infections with decreased susceptibility to cefixime, and this cluster was 
associated with sex partners from Asia.9 In addition, in 2006 to 2011 in CDC’s national 
Gonococcal Isolate Surveillance Project (GISP), the largest increase in the proportion of 
isolates with an elevated cefixime minimum inhibitory concentration (MIC) occurred in 
Hawaii.2 Monitoring trends in gonococcal antimicrobial susceptibility in Hawaii is critical to 
the surveillance for, early detection of, and response to the emergence of cephalosporin-
resistant N. gonorrhoeae in the United States.
Hawaii’s Gonorrhea Culture Screening Program (HGCSP), established in 1972, provides for 
the routine collection of specimens from patients at the public sexually transmitted disease 
(STD) clinic and several other clinical sites. β-Lactamase testing has been performed on all 
gonococcal isolates received through HGCSP since the mid-1970s.10 The HGCSP has also 
ensured antimicrobial susceptibility testing of all gonococcal isolates at the Hawaii State 
Laboratory Division since the early 1990s. This analysis reviewed trends in antimicrobial 
susceptibility among gonococcal isolates examined at Hawaii State Laboratory Division 
from 2003 to 2011 to assess whether the percent with elevated cephalosporin MICs has 
increased over time and to identify risk factors associated with elevated cephalosporin 
MICs. Ceftriaxone susceptibility testing was conducted throughout this period. Cefixime 
susceptibility testing was performed in 2003 and early 2004, discontinued in July 2004 when 
cefixime was no longer widely available, and then resumed in January 2010. Cefpodoxime 
susceptibility testing began in April 2004. Antimicrobial MICs were determined by Etest 
(bioMérieux, Saint Laurent, Quebec, Canada). Because MIC breakpoints that correspond to 
cefixime, cefpodoxime, and ceftriaxone resistance have not been established, “elevated 
MICs” were defined as the alert values used by the Hawaii State Department of Health: 
0.064 μg/mL or greater for cefixime, 0.19 μg/mL or greater for cefpodoxime, and 0.094 
μg/mL or greater for ceftriaxone.
The prevalences of elevated cefixime MICs by demographic characteristics and potential 
risk factors were examined for 2 periods, 2003 to 2004 (before cefixime susceptibility 
testing was discontinued) and 2010 to 2011 (after cefixime susceptibility testing was 
resumed). Because data on cefpodoxime susceptibility before mid-2004 were not available, 
demographic and risk factor analysis for cefpodoxime was restricted to the 2010 to 2011 
period. Basic demographic information and provider type were collected from all patients 
diagnosed as having gonorrhea and maintained in a surveillance database by the Hawaii 
State Department of Health. In addition, patients diagnosed as having gonorrhea at the 
public STD clinic were interviewed about exposure to potential risk factors in the 60 days 
before diagnosis, including sex of sex partner, travel, antimicrobial use, sex work or sexual 
contact with a sex worker, and military employment or sexual contact with military 
personnel.
Data were analyzed using SAS 9.2 (SAS Institute, Cary, NC). Prevalences in different 
populations were compared using prevalence ratios (PRs) and 95% confidence intervals 
(95% CIs).
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The percent of gonococcal isolates with an elevated cefixime MIC increased from 1.5% 
(7/482) in 2003 and 4.2% (6/142) in the first 6 months of 2004 to 17.3% (34/196) in 2010 
and 21.7% (40/184) in 2011 (P for trend <0.0001) (Fig. 1). When susceptibility testing for 
cefpodoxime was started in 2004, 1.5% (4/268) of isolates had an elevated cefpodoxime 
MIC. The proportion of isolates with an elevated cefpodoxime MIC remained less than 2% 
until 2009, when the proportion increased to 7.9% (16/202), and continued to increase to 
12.1% (26/214) in 2010 and 16.3% (30/184) in 2011 (P for trend <0.0001). The proportion 
of isolates with an elevated ceftriaxone MIC did not increase in 2003 to 2011 (P for trend = 
0.52). Two isolates with an elevated ceftriaxone MIC were identified by HGCSP during this 
period, both in 2005 (0.7% of 295 isolates in 2005).
Compared with 2003 to 2004, the prevalence of elevated cefixime MICs in 2010 to 2011 
increased in both males and females, in every age group, and in every race/ethnicity group 
(Table 1). In 2003 to 2004, the only demographic characteristic significantly associated with 
a higher prevalence of elevated cefixime MICs was residence outside of Hawaii; 2 (66.7%) 
of 3 patients from out of state (all 3 from California) had gonococcal isolates with an 
elevated cefixime MIC. In 2010 to 2011, prevalence of elevated cefixime MICs was higher 
in males compared with females (PR, 4.1; 95% CI, 1.7–9.8; P < 0.01) and, among 
interviewed patients at the STD clinic, higher in men who had sex with men (MSM) 
compared with men who had sex with women only (MSW; PR, 2.1; 95% CI, 1.04–4.3; P = 
0.03). Recent travel by patient or sex partner, antimicrobial use, sex work, and military 
affiliation were not associated with higher prevalence of elevated cefixime MIC in either 
period. Analysis of the prevalence of elevated cefpodoxime MICs by demographic 
characteristics and risk factors yielded similar results (data not shown). The prevalence of 
elevated cefpodoxime MICs in 2010 to 2011 was higher in males than in females (17.2% 
and 3.3%, respectively; PR, 5.2; 95% CI, 1.7–16.1; P < 0.01) and higher in MSM than in 
MSW, although this difference was not statistically significant (21.1% and 10.1%, 
respectively; PR, 2.1; 95% CI, 0.96–4.5; P = 0.07). In addition, recent antimicrobial use was 
associated with elevated cefpodoxime MICs (45.5% vs. 15.1%; PR, 3.0; 95% CI, 1.5–6.2; P 
< 0.01).
Surveillance of gonococcal susceptibility in Hawaii has national relevance because Hawaii 
is likely a site of importation of resistant gonorrhea from Asia. This may explain, in part, the 
increased prevalence of elevated cefixime and cefpodoxime MICs observed among 
gonococcal isolates in HGCSP from 2003 to 2004. These trends observed in HGCSP are 
similar to trends seen in GISP. Among GISP isolates from Hawaii, the percent of isolates 
with an elevated cefixime MIC (defined in GISP as MIC ≥0.25 μg/mL by agar dilution) 
increased from 0% in 2003 to 2004 to 13.1% in 2011; since GISP started testing for 
cefpodoxime susceptibility in 2009, the proportion of Hawaii isolates with an elevated 
cefpodoxime MIC (MIC ≥0.25 μg/mL by agar dilution) increased from 10.8% to 23.0% in 
2011 (GISP, unpublished data). In addition, as in HGCSP, the percent of GISP isolates from 
Hawaii with an elevated ceftriaxone MIC (MIC ≥0.125 μg/mL by agar dilution) has 
remained low; since 2003, GISP identified 2 Hawaii isolates with an elevated ceftriaxone 
MIC, one (1.3% of isolates) in 2010 and one (1.6% of isolates) in 2011.
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The increased prevalence of elevated cefixime MICs in HGCSP was observed in virtually 
every demographic group. However, in 2010 to 2011, the prevalence of elevated cefixime 
MICs was significantly higher in men than in women and higher in MSM than in MSW at 
the STD clinic. The same trend in MSM compared with MSW has been observed 
nationwide in GISP.2 The percent of patients with gonorrhea who were male increased in 
Hawaii from 43% in 2003 to 60% in 2011. Furthermore, the percent of male patients with 
gonorrhea who were MSM increased in the Honolulu STD clinic from 37% in 2003 to 68% 
in 2011. These findings emphasize the need to optimize gonorrhea treatment, partner 
services, and STD prevention among MSM to control gonorrhea and mitigate the spread of 
gonococcal strains with decreased susceptibility to cephalosporins in Hawaii and elsewhere.
There are some limitations to these data. Although it is clear that cefixime and cefpodoxime 
MICs are increasing, MIC breakpoints corresponding to cephalosporin resistance have not 
been established, and the clinical significance of elevated MICs, as described in this 
analysis, are not known. Hawaii’s Gonorrhea Culture Screening Program obtains isolates 
from 27% to 39% of gonorrhea cases in Hawaii each year; these data may not be 
representative of all gonorrhea cases in the state. However, no other state cultures such a 
high proportion of its cases, and this percentage is substantially higher than the 
approximately 4% of male patients sampled nationwide in GISP. A further advantage of 
HGCSP is that it includes women and asymptomatic patients and is therefore more inclusive 
and potentially more sensitive than GISP, which monitors susceptibility in symptomatic 
men, for identification of emerging resistant isolates. As an example, Hawaii detected the 
first gonococcal isolate in the United States with high-level resistance to azithromycin, an 
isolate that would have been missed if testing relied solely on GISP.11
Effective and timely treatment of cases is a cornerstone of gonorrhea control programs. The 
increased prevalence of elevated cefixime MICs in Hawaii underscores the importance of 
adhering to CDC’s treatment recommendations of dual treatment with ceftriaxone and either 
azithromycin or doxycycline. These data also highlight the value of HGCSP. Nationwide, 
expansion of local surveillance for gonococcal antimicrobial susceptibility could facilitate 
early detection of cases of cephalosporin resistance and a timely public health response. 
Continued surveillance in Hawaii for the emergence of antimicrobial resistance will be 
critical for the ongoing success of the local gonorrhea control program and for the national 
response to cephalosporin-resistant N. gonorrhoeae in the United States.
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Proportion of gonococcal isolates with an elevated cefixime MIC (MIC ≥0.064 μg/mL) and 
elevated cefpodoxime MIC (MIC ≥0.19 μg/mL)—HGCSP, 2003 to 2011. *There was no 
cefixime testing, July 2004 to December 2009; testing for cefpodoxime started in April 
2004.
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